Based on 10 analysts giving stock ratings to Mineralys Therapeutics Inc in the past month.
In the current month, MLYS has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. MLYS average Analyst price target in the last month is 45.222.
Based on analysts' estimates, MLYS EPS is projected to reach -0.589 in FY2026Q4, following reported EPS of -0.644 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.64, while Mineralys Therapeutics IncMLYS's earnings per share (EPS) for the previous quarter was USD -2.85. EPS for the next quarter is expected at USD -0.59.